RadioGel™ Cancer Therapy
RadioGel is an Yttrium-90 based injectable Precision Radionuclide Therapy (PRnT) device
for the treatment of cancerous tumors in animals (IsoPet®) and humans (RadioGel™).
Precision Radionuclide Therapy (PRnT) uses highly localized radiation to destroy,
cancerous tumors by placing a radioactive isotope directly inside the treatment
area using the company’s proprietary hydrogel technology.
Learn more
RadioGel™ – Cancer therapy for humans.
Radiogel™ is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
Learn More
IsoPet® – Cancer therapy for animals
The Isopet® Solutions division utilized university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. Testing on feline sarcoma at the Washington State University was completed in 2018 and testing on canine soft tissue sarcomas at the University of Missouri was completed in 2019.
IsoPet® Therapy is readily available at The University of Missouri and select Regional Clinics.
Learn More
( Mike Korenko, Sc.D • CEO • President | May 12, 2022 Press Release )
May 12, 2022 • Vivos Inc. Provides Intellectual Property Protection Update
Richland WA, May 12, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it expanded its intellectual property protection on several fronts.
Our patent team filed our particle patent in more than ten patent offices that collectively cover 63 countries throughout the world. This year we also filed a provisional patent number 63-299,930 giving us broader protection on recent and projected developments on both our hydrogel and our particle components. This week we filed a continuation-in-part applications number 1774054 in the USA to expand the claims on our particle patent.
We are near completion on additional development work and intend to file expanded particle claims internationally using the Patent Cooperation Treaty, PCT, process. Additionally, building on the substantial refinements to our hydrogel during the past two years, we also plan to file a new utility patent to protect these proprietary developments. We anticipate the filings will be completed during the third quarter.
In closing Dr. Korenko stated, “We are continually striving to enhance and grow our Intellectual property portfolio to build value to our stakeholders and to strengthen our position as an emerging leader in precision radionuclide therapy.”
Home Page Cover Image:
Veterinarian Dr. Michelle Myer from Vista Veterinarian Hospital in Kennewick, WA.
Seen here administering IsoPet® therapy to a feline suffering from a sarcoma.
RadioGel™ is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
IsoPet® Therapy Application(s)
Precision Radionuclide Therapy (PRnT)
Vivos Inc. - (OTCQB:RDGL) Investor Relations
Contact
| bg-primary | |
| bg-primary-light | |
| bg-primary-dark | |
| bg-secondary | |
| bg-secondary-dark |
| body | |
| top-header | |
| header | |
| content |
| background | |
| text color | |
| link color | |
| horizontal line |
| style 1 | |
| style 2 | |
| style 3 |
| social icons | |
| navigation color | |
| subnav background |
| background color | |
| navigation color |
Note: All changes made here will be applied to your entire website.
